Neonatal Nutrition and Gastroenterology Program, Cumming School of Medicine, University of Calgary, Calgary AB, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary AB, Canada.
Neonatal Nutrition and Gastroenterology Program, Cumming School of Medicine, University of Calgary, Calgary AB, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary AB, Canada.
Am J Clin Nutr. 2023 May;117(5):918-929. doi: 10.1016/j.ajcnut.2023.01.007. Epub 2023 Apr 19.
Preterm infants are at risk of long-chain polyunsaturated fatty acid (LCPUFA) deficiency. Recent studies on high-dose DHA; n-3 LCPUFA in preterm infants suggested potential positive effects on cognitive outcomes but raised concerns about some increased neonatal morbidities. These studies and recent recommendations for DHA supplementation generated controversy owing to the lack of balance between DHA and arachidonic acid (ARA; n-6 LCPUFA).
To identify the effect of enteral supplementation of DHA, with and without ARA, on necrotizing enterocolitis (NEC) in very preterm infants.
A systematic review of randomized and controlled trials compared enteral LCPUFAs with placebo or no supplementation in very preterm infants. We searched PubMed, Ovid-MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and CINHAL databases from inception to July 2022. Data were extracted in duplicate using a structured proforma. A meta-analysis and metaregression with random-effects models were used. The interventions evaluated were DHA alone vs. that combined with ARA, source of DHA, dose, and supplement delivery methods. Methodological qualities and risk of bias were assessed using the Cochrane risk-of-bias tool.
Fifteen randomized clinical trials (RCTs) included 3963 very preterm infants with 217 cases of NEC. Supplementation with DHA alone increased NEC (2620 infants; RR: 1.56; 95% CI: 1.02, 2.39) with no evidence of heterogeneity (I = 0.0%, P = 0.46). Multiple metaregression revealed significant reduction in NEC when ARA was supplemented with DHA (aRR 0.42; 95% CI: 0.21, 0.88). The source of DHA, dose, and feeding type revealed no associations with NEC. Two RCTs supplemented high-dose DHA to lactating mothers. There was a significant increase in risk of NEC with this approach (1148 infants; RR: 1.92; 95% CI: 1.02, 3.61) with no evidence of heterogeneity (I = 0.0, P = 0.81).
Supplementation with DHA alone may increase risk of NEC. Concurrent supplementation with ARA needs to be considered when adding DHA to preterm infants' diet.
早产儿存在长链多不饱和脂肪酸(LCPUFA)缺乏的风险。最近关于高剂量 DHA;n-3 LCPUFA 在早产儿中的研究表明,其对认知结果可能有积极影响,但也引起了一些新生儿发病率增加的担忧。这些研究以及最近对 DHA 补充的建议因 DHA 与花生四烯酸(ARA;n-6 LCPUFA)之间缺乏平衡而引发争议。
确定肠内补充 DHA,有或没有 ARA,对极早产儿坏死性小肠结肠炎(NEC)的影响。
系统综述了随机对照试验,比较了肠内 LCPUFA 与安慰剂或无补充剂在极早产儿中的效果。我们检索了 PubMed、Ovid-MEDLINE、EMBASE、Cochrane 对照试验中心注册数据库和 CINHAL 数据库,检索时间截至 2022 年 7 月。使用结构化表格重复提取数据。使用随机效应模型进行荟萃分析和荟萃回归。评估的干预措施是 DHA 单独与 DHA 联合 ARA、DHA 的来源、剂量和补充剂的输送方法。使用 Cochrane 偏倚风险工具评估方法学质量和偏倚风险。
纳入了 15 项随机临床试验(RCT),包括 3963 名极早产儿,其中 217 例发生 NEC。单独补充 DHA 增加了 NEC(2620 名婴儿;RR:1.56;95%CI:1.02,2.39),且无异质性(I = 0.0%,P = 0.46)。多次荟萃回归显示,当 DHA 与 ARA 联合补充时,NEC 显著减少(aRR 0.42;95%CI:0.21,0.88)。DHA 的来源、剂量和喂养方式与 NEC 无关联。两项 RCT 向哺乳期母亲补充高剂量 DHA。这种方法增加了 NEC 的风险(1148 名婴儿;RR:1.92;95%CI:1.02,3.61),且无异质性(I = 0.0,P = 0.81)。
单独补充 DHA 可能会增加 NEC 的风险。当在早产儿饮食中添加 DHA 时,需要考虑同时补充 ARA。